What is clomiphene / enclomiphene for testosterone — how does it compare to TRT?

Clomiphene citrate (off-label use) and enclomiphene (selective estrogen receptor modulator) stimulate the hypothalamic-pituitary axis to increase LH and FSH secretion, stimulating endogenous testosterone production, achieving testosterone increases of 150–300 ng/dL above baseline in most hypogonadal men while preserving spermatogenesis, making them the preferred option for men under 45 with fertility goals or men who want to avoid HPG axis suppression (Khera et al., J Urol, 2016).

The trade-offs relative to TRT: clomiphene/enclomiphene do not achieve the same testosterone levels as injectable TRT in most men (they stimulate within the physiological production range, not to supraphysiological levels); they can cause visual disturbances at higher doses (clomiphene more than enclomiphene); and they require an intact HPG axis to work, men with primary testicular failure (low testosterone from testicular dysfunction rather than pituitary signaling deficit) do not respond well. Enclomiphene (Natesto's active component) is more selective for the ER-alpha receptor in the hypothalamus than clomiphene, with fewer estrogen agonist effects at peripheral tissues.

Honesty Scale: Solid (1) for clomiphene/enclomiphene as fertility-preserving testosterone-stimulation options. Solid (1) for the limitation in primary hypogonadism.

What to do: If you are under 45 and want to treat hypogonadism while preserving fertility, ask your physician specifically about enclomiphene or clomiphene before TRT. If your LH and FSH are already elevated (indicating primary gonadal failure rather than secondary hypogonadism from HPG underactivation), SERMs will not work, you need exogenous testosterone.

For the full picture, read The Testosterone/TRT Deep Dive